Is Glaukos (GKOS) A Bargain After Its Big Run Higher?

Glaukos (GKOS) has drawn fresh attention after recent trading, which left the stock with a year-to-date total return above 50% and a 1-year total return above 110%.

The latest share price of $171.09 comes after a 34.2% 3-month share price return and a much stronger 1-year total shareholder return of 112.2%. This suggests momentum in Glaukos has been building even with a recent 7.3% pullback over the past month.

Scan beyond Glaukos and review a curated 35 high quality undervalued stocks featuring companies with strong cash flows and balance sheets that might not yet be fully reflected in their share prices.

Bulls argue Glaukos deserves its surge on growth in ophthalmic therapies. Bears point to the ongoing losses and rich expectations. The valuation work now has to show which side the current price supports.

Most Popular Narrative: 13% Undervalued

Glaukos is currently trading at $171.09, while the most followed narrative pegs fair value closer to $196.46, using a 7.49% discount rate to frame that gap. The story backing that estimate leans heavily on how iDose TR and a broader ophthalmic pipeline could reshape the business mix over time.

Strong ongoing adoption and utilization of iDose TR, a first-of-its-kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies. This is seen as a substantial long-term opportunity given the aging population and rising prevalence of glaucoma, likely driving robust multi-year revenue and market expansion.

See why 2 investors see Glaukos as 13% undervalued.

Result: Fair Value of $196.46 (UNDERVALUED)

Still, the Glaukos story can be knocked off course if reimbursement tightens or if new glaucoma and corneal therapies from rivals slow iDose and Epioxa uptake.

Find out about the key risks to this Glaukos narrative.

Another View on Glaukos Valuation

Glaukos appears inexpensive when evaluated on projected cash flows, with the stock at $171.09 and the SWS DCF model indicating a future cash flow value of $379.80. That is a large gap. The tension is that the same market paying a premium based on momentum could also reduce expectations quickly if sentiment cools.

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Mixed messages around Glaukos can make it hard to tell whether optimism or caution should carry more weight, so treat this as your prompt to review the numbers, read the filings, and weigh both sides carefully before the market moves on. To frame that decision with a quick snapshot of the bull points and the key concerns, start with 2 key rewards and 1 important warning sign.

Looking for more ideas beyond Glaukos?

If Glaukos has you thinking harder about where to put fresh capital, use this moment to widen your watchlist with a few focused stock ideas.

• Target potential mispricing by scanning a curated group of quality companies through the 35 high quality undervalued stocks.
• Strengthen portfolio resilience by reviewing a list of solid balance sheet and fundamentals (23 results) that can help anchor returns when conditions get choppy.
• Hunt for early-stage potential by checking a 3 elite penny stocks with strong financials that highlights smaller businesses with room for future development.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com